No Yes Ok

Archive

« Older Entries Newer Entries »

Is a cure for cancer finally within reach? Wednesday, December 6th, 2017
To read the full article click here [...]
LSP's portfolio company Affimed described Monday, December 4th, 2017
To read the full article click here. [...]
Kuros Biosciences May Secure Equity Financing of up to CHF 30 million Wednesday, November 22nd, 2017
Schlieren (Zurich), Switzerland, November 22, 2017 - Kuros (SIX: KURN) announced today it has entered into a Standby Equity Distribution Agreement (“SEDA”) with a fund managed by Yorkville Advisors Global, LLC ( [...]
LSP’s portfolio company Xeltis raises a substantial new round Thursday, November 16th, 2017
Amsterdam, the Netherlands, November 16, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces that its portfolio company Xeltis has raised a substantial new round. The clinical- [...]
LSP’s portfolio company Orphazyme raises approximately €80 million in oversubscribed IPO Thursday, November 16th, 2017
Amsterdam, The Netherlands – 16 November 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company Orphazyme was successfully listed [...]
LSP portfolio company Nouscom raises € 42m Series B round Monday, November 6th, 2017
Financing to advance its pipeline of neoantigen cancer based immunotherapies to the clinic   Basel, Switzerland – 6 November 2017: NousCom, an oncology company developing neoantigen based cancer vaccines ba [...]
argenx launches Phase I trial with subcutaneous formulation of ARGX-113 Monday, October 30th, 2017
Subcutaneous formulation intended for chronic therapy setting   October 30, 2017, Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing [...]
argenx reports third quarter 2017 financial results and provides business update Thursday, October 26th, 2017
October 26, 2017, Breda, the Netherlands / Ghent, Belgium argenx (Euronext Brussels & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome Tuesday, October 24th, 2017
Copenhagen, Denmark, October 24, 2017 - The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation to glepaglutide for the treatment of the rare dis [...]
Smith & Nephew acquires tissue regeneration technology for shoulder repair Monday, October 23rd, 2017
Amsterdam, the Netherlands, October 24, 2017 - Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces that it has entered into a definitive agreement to acquire Rotation Medical [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

Is a cure for cancer finally within reach? Wednesday, December 6th, 2017
To read the full article click here [...]
LSP's portfolio company Affimed described Monday, December 4th, 2017
To read the full article click here. [...]
Kuros Biosciences May Secure Equity Financing of up to CHF 30 million Wednesday, November 22nd, 2017
Schlieren (Zurich), Switzerland, November 22, 2017 - Kuros (SIX: KURN) announced today it has entered into a Standby Equity Distribution Agreement (“SEDA”) with a fund managed by Yorkville Advisors Global, LLC ( [...]
LSP’s portfolio company Xeltis raises a substantial new round Thursday, November 16th, 2017
Amsterdam, the Netherlands, November 16, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces that its portfolio company Xeltis has raised a substantial new round. The clinical- [...]
LSP’s portfolio company Orphazyme raises approximately €80 million in oversubscribed IPO Thursday, November 16th, 2017
Amsterdam, The Netherlands – 16 November 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company Orphazyme was successfully listed [...]
LSP portfolio company Nouscom raises € 42m Series B round Monday, November 6th, 2017
Financing to advance its pipeline of neoantigen cancer based immunotherapies to the clinic   Basel, Switzerland – 6 November 2017: NousCom, an oncology company developing neoantigen based cancer vaccines ba [...]
argenx launches Phase I trial with subcutaneous formulation of ARGX-113 Monday, October 30th, 2017
Subcutaneous formulation intended for chronic therapy setting   October 30, 2017, Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing [...]
argenx reports third quarter 2017 financial results and provides business update Thursday, October 26th, 2017
October 26, 2017, Breda, the Netherlands / Ghent, Belgium argenx (Euronext Brussels & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome Tuesday, October 24th, 2017
Copenhagen, Denmark, October 24, 2017 - The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation to glepaglutide for the treatment of the rare dis [...]
Smith & Nephew acquires tissue regeneration technology for shoulder repair Monday, October 23rd, 2017
Amsterdam, the Netherlands, October 24, 2017 - Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces that it has entered into a definitive agreement to acquire Rotation Medical [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund